What Eupraxia Pharmaceuticals does

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company headquartered in Victoria, British Columbia, and dual-listed on NASDAQ and the TSX under the ticker EPRX. Founded in 2012, the company develops locally delivered, extended-release therapies using its proprietary Diffusphere™ platform, a polymer-based micro-sphere technology that coats active drug compounds with a micron-thin polymer membrane enabling controlled, constant-rate release directly at the disease site while minimizing systemic exposure. Eupraxia's pipeline is anchored by two fluticasone propionate-based candidates: EP-104GI, an injectable esophageal formulation for eosinophilic esophagitis (EoE) currently in the Phase 1b/2a RESOLVE trial with positive 36- and 52-week data, and EP-104IAR, an intra-articular injection for knee osteoarthritis that has completed the Phase 2 SPRINGBOARD trial and received FDA Fast Track designation.

The company's intended customer segments are EoE patients (over 450,000 affected in the US) and knee OA patients (over 30 million in the US, 500 million globally), in both cases targeting indications where current standard-of-care delivers short duration of effect and high non-adherence. Eupraxia is also positioning Diffusphere™ as a platform extensible to additional inflammatory, pain, and oncology indications, with stated intent to expand into esophageal strictures and fibrostenotic Crohn's disease. Manufacturing is performed via US-based third-party contract manufacturers, and the company currently has no commercial product revenue, no disclosed pricing, and no expanded access program—patients can access investigational therapy only through clinical trial enrollment.

Name

Eupraxia Pharmaceuticals

Legal name

Eupraxia Pharmaceuticals Inc.

Website

https://eupraxiapharma.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

51–100 employees

Short description

Eupraxia Pharmaceuticals is a clinical-stage Canadian biotech developing locally delivered, extended-release therapeutics via its proprietary Diffusphere™ polymer micro-sphere platform, with two lead fluticasone propionate candidates: EP-104GI for eosinophilic esophagitis and EP-104IAR for knee osteoarthritis.

Ownership category

akta.pro rank

Product category

Clinical-stage biopharmaceuticals / Specialty drug delivery

NAICS

Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

Keywords

• Extended-release drug delivery
• Clinical-stage biopharmaceuticals
• Eosinophilic esophagitis therapy
• Knee osteoarthritis treatment
• Localized polymer drug delivery

Headquarters

HQ city

Victoria

HQ country

Canada

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

1. Product Sales (Pharmaceuticals): Eupraxia plans to commercialize its drug candidates (EP-104GI for EoE, EP-104IAR for knee OA) upon regulatory approval. As a clinical-stage biotechnology company, they do not currently generate product revenue.
2. Licensing and Partnership Revenue: The company may pursue licensing agreements or partnerships to expand Diffusphere technology across therapeutic areas including inflammatory diseases, pain conditions, and oncology indications.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company developing targeted, locally delivered extended-release therapies using its proprietary Diffusphere™ polymer micro-sphere platform. Its lead product candidate, EP-104GI, is an injectable, controlled-release fluticasone propionate formulation being studied for eosinophilic esophagitis in a Phase 1b/2a RESOLVE trial, while EP-104IAR, a long-acting intra-articular fluticasone propionate injection for knee osteoarthritis, has completed a Phase 2 SPRINGBOARD trial. The platform coats active drug compounds with a micron-thin polymer membrane that releases the drug at a defined, constant rate at the site of disease, intended to minimize systemic exposure while providing sustained therapeutic effect.

Product overview

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company developing targeted therapies leveraging its proprietary Diffusphere™ extended-release drug delivery technology. The company's clinical pipeline consists of two product candidates: EP-104GI for the treatment of Eosinophilic Esophagitis (EoE), currently in Phase 1b/2a RESOLVE clinical trial, and EP-104IAR for the treatment of Knee Osteoarthritis pain, which has completed Phase 2 SPRINGBOARD clinical trial. The Diffusphere technology is designed to deliver the right dose of drug, in the right place, for the right duration by coating active compounds with a polymer membrane that releases at a constant rate, minimizing systemic exposure while maximizing local therapeutic effect.

Differentiator

Problem solved

Functional benefit

Products and services

• Diffusphere™ Extended-Release Technology Platform A proprietary polymer-based micro-sphere technology that coats active drug compounds with a micron-thin polymer membrane to release drug at a defined, constant rate at the site of disease, intended to minimize systemic exposure and enable sustained local therapeutic effect across inflammatory diseases, pain conditions, and oncology indications.
• EP-104GI A long-acting, controlled-release fluticasone propionate formulation designed to be injected into esophageal tissue for the treatment of eosinophilic esophagitis (EoE); currently being evaluated in the Phase 1b/2a RESOLVE trial, with 66% of patients maintaining clinical remission through 36 weeks and 67% through 52 weeks after a single treatment in clinical results to date.
• EP-104IAR A long-acting, controlled-release fluticasone propionate formulation designed to be injected into the intra-articular space for the treatment of knee osteoarthritis pain; completed Phase 2 SPRINGBOARD trial (meeting primary endpoint and 3 of 4 secondary endpoints), granted FDA Fast Track designation, and Phase 2 results published in The Lancet Rheumatology (Volume 6, pages e860-70).

Quantifiable outcome

• EP-104GI Phase 1b/2a RESOLVE trial: 66% of patients maintained clinical remission through week 36 after single treatment
• +4 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered minor.

• Canadian Investment Regulatory Organization (CIRO)minorOthers · 9 March 2026Trading halt implemented due to pending delisting from TSX. Temporary regulatory measure to maintain fair trading practices.
• American Partnership for Eosinophilic Disorders (APFED)minorStrategic or Co-development PartnerPatient advocacy organization partner providing resources and support for EoE patients. Listed as a resource on Eupraxia's patient information page.
• EOS NetworkminorStrategic or Co-development PartnerUK-based global nonprofit fostering patient, professional, and research collaboration around EGIDs such as EoE. Listed as a patient resource.
• Arthritis FoundationminorStrategic or Co-development PartnerUS nonprofit supporting individuals living with arthritis through community awareness, policy advocacy, and significant investment in research. Listed as resource for knee osteoarthritis patients.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Ellodi Pharmaceuticals: Privately-held, EoE-focused clinical-stage biotech developing targeted therapies for eosinophilic gastrointestinal diseases. Closest direct competitor to Eupraxia's EP-104GI program, pursuing novel local delivery approaches to EoE.
• Pacira BioSciences: Public specialty pharma (NASDAQ: PCRX) built around extended-release, locally delivered therapeutics including EXPAREL (long-acting local anesthetic) and the Zilretta intra-articular steroid acquired from Flexion Therapeutics. Most analogous platform peer to Eupraxia's Diffusphere and EP-104IAR.
• Heron Therapeutics: Public specialty pharma (NASDAQ: HRTX) developing extended-release polymer-based injectable therapeutics (e.g., Zynrelef, Sustol, APONVIE). Directly comparable to Eupraxia in using proprietary extended-release delivery technology to improve duration and tolerability of approved drugs.
• Anika Therapeutics: Public specialty pharma (NASDAQ: ANIK) developing intra-articular hyaluronic acid therapies and other osteoarthritis pain treatments including Cingal and Monovisc. Direct comparator to Eupraxia's EP-104IAR intra-articular knee OA program.
• Bioventus: Public orthopedic specialty company offering intra-articular knee OA pain treatments including hyaluronic acid and steroid injections. Direct competitor to Eupraxia's EP-104IAR in the same physician call point and patient population.

Broad incumbents

• Takeda Pharmaceutical: Global pharma with Eohilia (budesonide oral suspension) approved for EoE, the most direct competitive incumbent in Eupraxia's lead EoE indication. As a broad incumbent, offers an alternative approved therapy but not a local extended-release specialist like Eupraxia.
• Sanofi/Regeneron (Dupixent): Dupixent (dupilumab) is approved for EoE among other indications, representing the most commercially entrenched systemic biologic competing in the EoE space Eupraxia is targeting with EP-104GI. Broad incumbent with deep commercial reach rather than a local-delivery specialist.

Regional players

• Seikagaku Corporation: Japanese specialty pharma with multiple approved intra-articular hyaluronic acid injections for knee osteoarthritis (e.g., Supartz, Gel-One). Comparable therapeutic approach to EP-104IAR but primarily serves the Japanese market rather than the US/EU.

Emerging players

• Innocoll Pharmaceuticals: Specialty pharma developing locally administered collagen-based drug delivery platforms for post-surgical pain and other indications. Comparable to Eupraxia in pursuing site-specific, extended-release delivery to reduce systemic exposure.
• Aurinia Pharmaceuticals: Public clinical-stage/specialty pharma (NASDAQ: AUPH) co-founded by Richard Glickman, who serves on Eupraxia's board. Comparably sized Canadian-headquartered specialty biotech with a commercial-stage asset (Lupkynis) — useful as a size, governance, and stage-of-evolution benchmark for Eupraxia as it transitions to commercialization.

Market position

Strengths3 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Eupraxia_Pharma
• LinkedInlinkedin.com/company/eupraxia-pharmaceuticals-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries4 records

Funding overview

Funding rounds9 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eupraxia Pharmaceuticals